

29 December 2022

## Nivolumab and other cancer drug treatments

The initiation of patient treatment with Nivolumab and some additional products in different types of cancer.

Information as available from RISOH (Regional Information System Oncology and Haematology) September – November 2022

Q1. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of melanoma?

- Nivolumab (monotherapy) : <5
- Nivolumab AND Ipilimumab (combination) : 12

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of Renal Cell Carcinoma?

- Nivolumab (monotherapy) : 6
- Nivolumab + Ipilimumab : <5
- Nivolumab + Cabozantinib : 8
- Avelumab + Axitinib : <5

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated\* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)?

- Nivolumab : <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) : <5

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

**Use of < 5 (less than five):** We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.